RT Journal Article
SR Electronic
T1 Development of Reverse Phase Protein Microarrays for Clinical Applications and Patient-tailored Therapy
JF Cancer Genomics - Proteomics
JO Cancer Genomics Proteomics
FD International Institute of Anticancer Research
SP 157
OP 164
VO 4
IS 3
A1 RUNA SPEER
A1 JULIA WULFKUHLE
A1 VIRGINIA ESPINA
A1 ROBYN AURAJO
A1 KIRSTEN H. EDMISTON
A1 LANCE A. LIOTTA
A1 EMANUEL F. PETRICOIN III
YR 2007
UL http://cgp.iiarjournals.org/content/4/3/157.abstract
AB While genomics provide important information about the somatic genetic changes, and RNA transcript profiling can reveal important expression changes that correlate with outcome and response to therapy, it is the proteins that do the work in the cell. At a functional level, derangements within the proteome, driven by post-translational and epigenetic modifications, such as phosphorylation, is the cause of a vast majority of human diseases. Cancer, for instance, is a manifestation of deranged cellular protein molecular networks and cell signaling pathways that are based on genetic changes at the DNA level. Importantly, the protein pathways contain the drug targets in signaling networks that govern overall cellular survival, proliferation, invasion and cell death. Consequently, the promise of proteomics resides in the ability to extend analysis beyond correlation to causality. A critical gap in the information knowledge base of molecular profiling is an understanding of the ongoing activity of protein signaling in human tissue: what is activated and “in use” within the human body at any given point in time. To address this gap, we have invented a new technology, called reverse phase protein microarrays, that can generate a functional read-out of cell signaling networks or pathways for an individual patient obtained directly from a biopsy specimen. This “wiring diagram” can serve as the basis for both, selection of a therapy and patient stratification.